Tocilizumab and refractory Takayasu disease: Four case reports and systematic review.
Fiche publication
Date publication
avril 2018
Journal
Autoimmunity reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Pr OLIVIER Pierre
Tous les auteurs :
Decker P, Olivier P, Risse J, Zuily S, Wahl D
Lien Pubmed
Résumé
Relapses upon corticosteroids tapering and immunosuppressive agents are frequent in Takayasu arteritis (TA). Interleukin-6 is highly involved in physiopathology of TA. Many reports showed efficacy of tocilizumab (TCZ) in refractory TA cases. We report four cases and an updated literature review on the TCZ efficacy and safety in patients with TA.
Mots clés
Anti-IL 6 antibody, Large vessel vasculitis, Systematic review, Takayasu arteritis, Therapy, Tocilizumab
Référence
Autoimmun Rev. 2018 Apr;17(4):353-360